Did you know?
ChinaBio® Group is an investment, consulting and media firm helping western life science companies achieve success in China. ChinaBio works with U.S., European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China.  

>> Learn more…

Site Search

>> Advanced Search

  Quick Search:

Free Newsletter

  Email address:

Watson Pharma Buys Actavis in a Marriage of Generic Drugmakers

publication date: Apr 26, 2012
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
Watson Pharmaceuticals of the US acquired privately held Actavis Group at a price of about $5.6 billion upfront, plus earn-out provisions based on 2012 results. Both companies are large generic drug manufacturers, and together they will constitute the third biggest generic drug company in the world. Although neither company has a huge presence in China – only about 2% of Watson’s revenues currently come from Asia – the acquisition will add to Watson’s presence in both China and India. More details....

Stock Symbol: (NYSE: WPI)

Share this with colleagues:  

This article is available for purchase - please click here for details.

Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...